National trends in alcohol pharmacotherapy: Findings from an Australian claims database

Drug and Alcohol Dependence

Volumn 166, Issue , 2016, Pages 254-257

  Morley, Kirsten C ^a   Logge, Warren ^b   Pearson, Sallie Anne ^c   Baillie, Andrew ^b   Haber, Paul S ^a,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Acamprosate; Alcohol dependence; Naltrexone; Pharmacotherapy; Prescription

Indexed keywords

ACAMPROSATE; NALTREXONE; DRUGS USED IN THE TREATMENT OF ADDICTION; TAURINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALCOHOLISM; ARTICLE; AUSTRALIA; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG COST; FEMALE; GENDER; HUMAN; MALE; MEDICATION COMPLIANCE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; VERY ELDERLY; ALCOHOL ABSTINENCE; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG ADMINISTRATION; INSURANCE; PATIENT COMPLIANCE; PROTOCOL COMPLIANCE; STATISTICS AND NUMERICAL DATA;

ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; AUSTRALIA; DRUG ADMINISTRATION SCHEDULE; FEMALE; GUIDELINE ADHERENCE; HUMANS; INSURANCE CLAIM REVIEW; MALE; NALTREXONE; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; TAURINE; TEMPERANCE;

EID: 84979710848     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2016.06.027     Document Type: Article

References (33)

1. Anton, R.F., O'Malley, S.S., Ciraulo, D.A., Cisler, R.A., Couper, D., Donovan, D.M., Gastfriend, D.R., Hosking, J.D., Johnson, B.A., LoCastro, J.S., Longabaugh, R., Mason, B.J., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295 (2006), 2003–2017.
2. Bauer, A.M., Schillinger, D., Parker, M.M., Katon, W., Adler, N., Adams, A.S., Moffett, H.H., Karter, A.J., Health literacy and antidepressant medication adherence among adults with diabetes: the diabetes study of Northern California (DISTANCE). J. Gen. Intern. Med. 28 (2013), 1181–1187.
3. Bouza, C., Angeles, M., Munoz, A., Amate, J.M., Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99 (2004), 811–828.
4. Brown, M.T., Bussell, J.K., Medication adherence: WHO cares?. Mayo Clin. Proc. 86 (2011), 304–314.
5. Buri, C., Moggi, F., Giovanoli, A., Strik, W., Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland. Alcohol Alcohol. 42 (2007), 333–339.
6. Chapman, C., Slade, T., Hunt, C., Teesson, M., Delay to first treatment contact for alcohol use disorder. Drug Alcohol Depend. 147 (2015), 116–121.
7. Chick, J., Howlett, H., Morgan, M.Y., Ritson, B., United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 35 (2000), 176–187.
8. Collins, D.J., Lapsley, H.M., 2008. The Costs Of Tobacco, Alcohol And Illicit Drug Abuse To Australian Society In 2004/05, National Drug Strategy Monograph Series No. 64, http://www.health.gov.au/pubhlth/publicat/document/mono64.pdf.
9. Doran, C.M., Fawcett, J.E., Shakeshaft, A.P., Shanahan, M.D., Mattick, R.P., New pharmacotherapies for alcohol dependence: are they being used and what do they cost?. Med. J. Aust., 197, 2003, 218.
10. Harris, K.M., Thomas, C., Naltrexone and pharmacy benefit management. J. Addict. Dis. 23 (2004), 11–129.
11. Johnson, B.A., O'Malley, S.S., Ciraulo, D.A., Roache, J.D., Chambers, R.A., Sarid-Segal, O., Couper, D., Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J. Cin. Psychopharmacol. 23 (2003), 281–293.
12. Jonas, D.E., Amick, H.R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M.M., Shanahan, E., Gass, C.E., Rowe, C.J., Garbutt, J.C., Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 311 (2014), 1889–1900.
13. Kiefer, F., Wiedemann, K., Combined therapy: what does acamprosate and naltrexone combination tell us?. Alcohol Alcohol. 39 (2004), 542–547.
14. Kiefer, F., Jahn, H., Tarnaske, T., Helwig, H., Briken, P., Holzbach, R., Kampf, P., Stracke, R., Baehr, M., Naber, D., Wiedemann, K., Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry 60 (2003), 92–99.
15. Kranzler, H.R., Escobar, R., Lee, D.K., Meza, E., Elevated rates of early discontinuation from pharmacotherapy trials in alcoholics and drug abusers. Alcohol. Clin. Exp. Res. 20 (1996), 16–20.
16. Laslett, A., Catalano, P., Chikritzhs, T., The Range and Magnitude of Alcohol's Harm to Others. Point, T., (eds.), 2010, AER Centre For Alcohol Policy Research, Fitzroy, Victoria.
17. Mark, T.L., Kranzler, H.R., Song, X., Understanding US addiction physicians’ low rate of naltrexone prescription. Drug Alcohol Depend. 71 (2003), 219–228.
18. Mark, T.L., Kranzler, H.R., Song, X., Bransberger, P., Poole, V.H., Crosse, S., Physicians’ opinions about medications to treat alcoholism. Addiction 98 (2003), 617–626.
19. Mellish, L., Karanges, E., Litchfield, M., Schaeffer, A.L., Blanch, B., Daniels, B.J., Segrave, A., Pearson, S.A., The Australian pharmaceutical benefits scheme data collection: a practical guide for researchers. BMC Res. Notes, 8, 2015, 634.
20. Morley, K.C., Teesson, M., Reid, S.C., SAnnibale, C., Thomson, C., Phung, N., Weltman, M., Bell, J.R., Richardson, K., Haber, P.S., Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 101 (2006), 1451–1462.
21. Morley, K.C., Lintzeris, N., Haber, P.S., Pharmacotherapies For Alcohol Dependence Guidelines For The Treatment of Alcohol Problems. 2009, Australian Government Department for Health and Aging, 93–106.
22. Morley, K.C., Baillie, A., Leung, S., Addolorato, G., Leggio, L., Haber, P.S., Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol. 49 (2014), 654–660.
23. Morley, K.C., Baillie, A., Leung, S., Sannibale, C., Teesson, M., Haber, P.S., Is specialized integrated treatment for comorbid anxiety, depression and alcohol dependence better than treatment as usual in a public hospital setting?. Alcohol Alcohol. 51:4 (2016), 402–409.
24. Osterberg, L., Blaschke, T., Adherence to medication. N. Engl. J. Med. 353 (2005), 487–497.
25. Proudfoot, H., Teesson, M., The association of alcohol dependence with general practice attendance. Drug Alcohol Rev. 28 (2009), 154–159.
26. Rösner, S., Hackl-Herrwerth, A., Leucht, S., Vecchi, S., Srisurapanont, M., Soyka, M., Opioid antagonists for alcohol dependence. Cochrane Database Syst. Rev., 12, 2010.
27. Rammes, G., Mahal, B., Putzke, J., Parsons, C., Spielmanns, P., Pestel, E., Spanagel, R., Zieglgansberger, W., Schadrack, J., The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 40 (2001), 749–760.
28. Sawada, N., Uchida, H., Suzuki, T., Watanabe, K., Kikuchi, T., Handa, T., Kashima, H., Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry, 9, 2009, 38.
29. Schroeder, K., Fahey, T., Ebrahim, S., How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch. Intern. Med. 164 (2004), 722–732.
30. Teesson, M., Hall, W., Slade, T., Mills, K., Grove, R., Mewton, L., Baillie, A., Haber, P., Prevalence and correlates of DSM-IV alcohol abuse and dependence in Australia: findings of the 2007 National Survey of Mental Health and Wellbeing. Addiction 105 (2010), 2085–2094.
31. Volpicelli, J.R., Rhines, K.C., Rhines, J.S., Volpicelli, L.A., Alterman, A.I., O'Brien, C.P., Naltrexone and alcohol dependence: role of subject compliance. Arch. Gen. Psychiatry 54 (1997), 737–742.
32. WHO, Global Information System on Alcohol and Health. 2015, World Health Organization, Geneva.
33. Yeaw, J., Benner, J.S., Walt, J.G., Sian, S., Smith, D.B., Comparing adherence and persistence across 6 chronic medication classes. JMCP 15 (2009), 728–740.